Transform Vascular Access With HydroMID® and HydroPICC®

The only drug-free catheters with an anti-thrombogenic indication from the FDA.*

Get Started

Solving the Most Common and Costly Complications in Vascular Access

AVI develops solutions for front-line clinicians like you who juggle placing lines, maintaining them, and dealing with complications from line failures.

Catheter complications often come down to the material the catheter is made from. Traditional catheters are made from a hydrophobic polyurethane material, which elicits a foreign body response. Central line catheters have 15-30% complication rates with occlusion, thrombosis, and infection being the most frequent complications.¹,² Additionally, central line catheter occlusions are common, affecting approximately 12% of catheters.³

Innovative Technology Designed to Reduce Thrombosis

Our HydroMID and HydroPICC catheters with MIMIX® technology feature a proprietary hydrogel material with anti-thrombogenic properties to help address catheter-related complications such as thrombosis and occlusion – potential sources of morbidity, readmissions, and cost for health systems.**

This innovation is designed to repel protein adsorption and create thromboresistance,² with no coatings, drugs, fillings, or surface modifications. Our catheters can help avoid the cascade of complications that come with traditional polyurethane catheters and provide a better patient experience.

  • Reduce Treatment Delays:

    Fewer catheter replacements means fewer unnecessary needle sticks, providing a better experience for both patients and nurses and keeping treatment on track.

  • Increase Dwell Time:

    Allows for extended therapy without the need for replacement or switching to more invasive devices, preventing the negative downstream effects.¹⁰

  • Lower Complication Rates:

    Less complications means less physical, emotional, and economic burdens on patients and healthcare systems.

No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

Get Started

Let the Catheter Material Work for You, Not Against You

Learn More
6X Fewer Complications

HydroMID®: Hydrophilic Midline Catheter

HydroMID, our midline catheter with MIMIX technology, was shown to significantly reduce complications in a retrospective clinical study of 205 patients.⁸

Learn More
Zero Occlusions or Replacements

HydroPICC®: Hydrophilic PICC Catheter

HydroPICC, our PICC catheter with MIMIX technology, was shown to completely eliminate occlusions and replacements in a retrospective study of 121 patients.⁹

Learn More

Ready to Reduce Catheter-Related Complications?

Take the first step toward reducing thrombosis and the costly complications that come with it. Learn more about bringing the anti-thrombogenic benefits of AVI’s MIMIX technology to your patients.

*K243458. The clinical impact has not been evaluated in human clinical trials.

**Pre-clinical in vitro/in vivo evaluations do not necessarily predict clinical performance

  1. N Engl J Med. 2025 Jan 9;392(2):161-172. doi: 10.1056/NEJMoa2406815.

  2. Moureau NL (2022). International Journal of Nursing Health Care Research 5: 1347. DOI: https://doi.org/10.29011/2688-9501.101347

  3. J Vasc Interv Radiol. 2017 May;28(5):749-756.e2. doi: 10.1016/j.jvir.2017.02.005. Epub 2017 Mar 11.

  4. J Infus Nurs. 2025 Nov-Dec;48(6):386-394. doi: 10.1097/NAN.0000000000000615. Reduction of thrombus accumulation was evaluated using in vitro models. Pre-clinical in vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation.

  5. J Infus Nurs. 2022 Sep-Oct;45(5):270-278. doi: 10.1097/NAN.0000000000000484.

  6. J Mater Sci Mater Med. 2023 Jul 21;34(7):34. doi: 10.1007/s10856-023-06736-0. Study conducted using the HydroPICC® Single Lumen Catheter.

  7. J Mech Behav Biomed Mater. 2023 Mar:139:105670. doi: 10.1016/j.jmbbm.2023.105670.
    LeRoy, K., & Donahue, D. (2025). In Vitro Venous Catheter Material Comparison: Microbial Adhesion in a Thrombotic Blood Flow Model. Journal of infusion nursing : the official publication of the Infusion Nurses Society, 48(6), 386–394. https://doi.org/10.1097/NAN.0000000000000615

  8. A Retrospective Assessment of Peripheral Catheter Failures Focusing on Catheter Composition. Journal of Infusion Nursing. 45(5):p 270-278, September/October 2022.

  9. A retrospective, comparative, clinical study of occlusion rate of peripherally inserted central catheters fabricated of poly(vinyl alcohol)-based hydrogel composite. Journal of Materials Science: Materials Science in Medicine (2023) 34:34.

  10. Data in this study was not comparative but represents published dwell time for standard TPU catheters. Read the whitepaper for details.

Hanley, B. (2024) Evaluation of Dwell Time of Hydrophilic Biomaterial Midline Catheters: A Product Evaluation.